ReviewFEMS microbiology reviews2017
Perspectives for clinical use of engineered human host defense antimicrobial peptides.
Review in FEMS microbiology reviews, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 76 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
76 citing papers in PubMed.
- Human histone fragments display antibacterial properties againstFrontiers in immunology · 2026Article
- Vitamin D-Induced Antimicrobial Peptides in Combating Viral Infections.Advances in experimental medicine and biology · 2026Review
- Resistance mechanisms of bacterial biofilms on orthopedic implants and research progress on novel anti-biofilm coatings.Frontiers in bioengineering and biotechnology · 2026Review
- The antimicrobial peptide EM86 loaded to gamma-irradiated sodium alginate/polyvinyl alcohol electrospun nanofibrous dressing treated multidrug-resistantFrontiers in bioengineering and biotechnology · 2026Article
- Vitamin D-AMP axis in host defense against fungal infections.Frontiers in nutrition · 2026Review
- Exploring the Antimicrobial Potential of a Peptide Against Mixed Biofilm of Staphylococcus aureus and Candida albicans.Probiotics and antimicrobial proteins · 2026Article
- Disentangling the impact of obesity, diet, host factors, and microbiota on small intestinal antimicrobial peptide expression.Gut microbes · 2025Article
- Human Defensins: Structure, Function, and Potential as Therapeutic Antimicrobial Agents with Highlights Against SARS CoV-2.Probiotics and antimicrobial proteins · 2025Review
- Review
- LL-37 regulates odontogenic differentiation of dental pulp stem cells in an inflammatory microenvironment.Stem cell research & therapy · 2024Article
- LiaR-dependent gene expression contributes to antimicrobial responses in group AAntimicrobial agents and chemotherapy · 2024Article
- Antiparasitic Evaluation of Aquiluscidin, a Cathelicidin Obtained fromPathogens (Basel, Switzerland) · 2024Article
- Tetrahedral framework nucleic acids/hyaluronic acid-methacrylic anhydride hybrid hydrogel with antimicrobial and anti-inflammatory properties for infected wound healing.International journal of oral science · 2024Article
- Neutrophil extracellular traps in bacterial infections and evasion strategies.Frontiers in immunology · 2024Review
- Immunomodulatory peptides: new therapeutic horizons for emerging and re-emerging infectious diseases.Frontiers in microbiology · 2024Review
- Recent advances in the therapeutic potential of cathelicidins.Frontiers in microbiology · 2024Review
- Endopeptidase O promotesVirulence · 2023Article
- Design methods for antimicrobial peptides with improved performance.Zoological research · 2023Review
- Small-Molecule Antibiotic Drug Development: Need and Challenges.ACS infectious diseases · 2023Review
- Resistance is futile: targeting multidrug-resistant bacteria withRSC chemical biology · 2023Review
16 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Infectious diseases caused by bacteria, viruses or fungi are among the leading causes of death worldwide. The emergence of drug-resistance mechanisms, especially among bacteria, threatens the efficacy of all current antimicrobial agents, some of them already ineffective. As a result, there is an urgent need for new antimicrobial drugs. Host defense antimicrobial peptides (HDPs) are natural occurring and well-conserved peptides of innate immunity, broadly active against Gram-negative and Gram-positive bacteria, viruses and fungi. They also are able to exert immunomodulatory and adjuvant functions by acting as chemotactic for immune cells, and inducing cytokines and chemokines secretion. Moreover, they show low propensity to elicit microbial adaptation, probably because of their non-specific mechanism of action, and are able to neutralize exotoxins and endotoxins. HDPs have the potential to be a great source of novel antimicrobial agents. The goal of this review is to provide an overview of the advances made in the development of human defensins as well as the cathelicidin LL-37 and their derivatives as antimicrobial agents against bacteria, viruses and fungi for clinical use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.